23:40 , Aug 14, 2019 |  BC Extra  |  Clinical News

Regeneron data could set up first-in-class approval in lipid-lowering indication

Regeneron's evinacumab could give certain hypercholesterolemia patients a new treatment option, with an FDA submission looming based on new results from a Phase III trial evaluating the first-in-class therapy as an add-on to existing treatments....
23:47 , May 23, 2019 |  BC Innovations  |  Tools & Techniques

As polygenic risk scores mature, opportunities emerge for disease interception

With comprehensive genetic risk profiling inching closer to clinical use, the biggest opportunity for drug developers could be the new territory it opens up in disease prevention and interception, particularly for common diseases. Much of...
19:14 , May 20, 2019 |  BC Extra  |  Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC  Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...
00:22 , Mar 5, 2019 |  BC Extra  |  Company News

Lilly offers cheaper insulin, pressuring competitors

Lilly will offer a new, lower cost insulin that is substitutable for Humalog at pharmacies. While at least one patient group says it's not enough, the move puts pressure on the pharma’s competitors. Months of...
19:56 , Mar 1, 2019 |  BC Week In Review  |  Company News

Jury upholds three Repatha patent claims

A jury upheld the validity of three of the five asserted claims covering two U.S. patents for PCSK9 inhibitor Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN). The jury found two of the claims of U.S. Patent...
18:09 , Feb 15, 2019 |  BC Week In Review  |  Company News

Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the $5,850 annual price of competitor LDL-C lowering drug Repatha evolocumab. Last year,...
22:40 , Feb 11, 2019 |  BC Extra  |  Company News

Sanofi, Regeneron cut Praluent list price by 60%

Sanofi (Euronext:SAN; NASDAQ:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are dropping the list price of PCSK9 inhibitor Praluent alirocumab by 60% to match the $5,850 annual price of competitor LDL-C lowering drug Repatha evolocumab. Last year,...
18:44 , Dec 14, 2018 |  BC Week In Review  |  Company News

As Medicines Co. seeks funding, Denner brings in new CEO

Business: Cardiovascular The Medicines Company (NASDAQ: MDCO) said Dec. 11 it hired Mark Timney as CEO and a director, succeeding long-running CEO Clive Meanwell. The announcement comes after activist investor Alex Denner became chairman in...
22:12 , Dec 11, 2018 |  BC Extra  |  Company News

As Medicines Co. seeks funding, Denner brings in new CEO

The Medicines Company (NASDAQ: MDCO) said Tuesday it hired Mark Timney as CEO and a director, succeeding long-running CEO Clive Meanwell. The announcement comes after activist investor Alex Denner became chairman in June, and follows...